Clinical application of artificial intelligence algorithm for prediction of one-year mortality in heart failure patients.

Journal: Heart and vessels
Published Date:

Abstract

Risk prediction for heart failure (HF) using machine learning methods (MLM) has not yet been established at practical application levels in clinical settings. This study aimed to create a new risk prediction model for HF with a minimum number of predictor variables using MLM. We used two datasets of hospitalized HF patients: retrospective data for creating the model and prospectively registered data for model validation. Critical clinical events (CCEs) were defined as death or LV assist device implantation within 1 year from the discharge date. We randomly divided the retrospective data into training and testing datasets and created a risk prediction model based on the training dataset (MLM-risk model). The prediction model was validated using both the testing dataset and the prospectively registered data. Finally, we compared predictive power with published conventional risk models. In the patients with HF (n = 987), CCEs occurred in 142 patients. In the testing dataset, the substantial predictive power of the MLM-risk model was obtained (AUC = 0.87). We generated the model using 15 variables. Our MLM-risk model showed superior predictive power in the prospective study compared to conventional risk models such as the Seattle Heart Failure Model (c-statistics: 0.86 vs. 0.68, p < 0.05). Notably, the model with an input variable number (n = 5) has comparable predictive power for CCE with the model (variable number = 15). This study developed and validated a model with minimized variables to predict mortality more accurately in patients with HF, using a MLM, than the existing risk scores.

Authors

  • Hiroyuki Takahama
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan. hiroytakahama@gmail.com.
  • Kunihiro Nishimura
    Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka 564-8565, Japan. Electronic address: knishimu@ncvc.go.jp.
  • Budrul Ahsan
    Philips Japan, Minato-Ku, Tokyo, 108-8507, Japan.
  • Yasuhiro Hamatani
    Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, 612-8555, Japan.
  • Yuichi Makino
    Philips Japan, Minato-Ku, Tokyo, 108-8507, Japan.
  • Shoko Nakagawa
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Yuki Irie
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Kenji Moriuchi
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Masashi Amano
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Atsushi Okada
    Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
  • Takeshi Kitai
  • Makoto Amaki
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Hideaki Kanzaki
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Teruo Noguchi
    Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
  • Kengo Kusano
    Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
  • Masaharu Akao
    Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, 612-8555, Japan.
  • Satoshi Yasuda
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.
  • Chisato Izumi
    Department of Cardiovascular Medicine, National Cerebral Cardiovascular Center, Suita, 564-8565, Japan.